Cat.No. : CSC-RO0400 Host Cell: Ba/F3
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0400 |
| Description | This cell line is engineered to stably overexpress exogenous human KIF5B-RET fusion protein bearing G810R mutation in RET part. |
| Target Gene | KIF5B-RET |
| Gene Species | Homo sapiens (Human) |
| Host Cell | Ba/F3 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Growth Conditions | 37 °C, 5% CO2 |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Biosafety Level | 2 |
| Thawing & Subculturing Instructions | 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL. |
| Growth Properties | Suspension, round |
| Freeze Medium | Frozen with 70% medium, 20% FBS, 10% DMSO |
| Freezing Instructions | Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
A: The KIF5B-RET-G810R gene is a fusion gene that results from the joining of the KIF5B and RET genes. This fusion is often found in thyroid cancer, particularly in medullary thyroid cancer. The G810R mutation is a specific variant within the RET gene that is associated with a more aggressive form of thyroid cancer.
A: The KIF5B-RET-G810R fusion gene contributes to cancer development by activating the RET tyrosine kinase. This activation leads to aberrant signaling, which promotes cell growth, invasion, and resistance to apoptosis. The G810R mutation further enhances the oncogenic potential of RET, contributing to a more aggressive disease.
A: Targeting the KIF5B-RET-G810R fusion gene has significant therapeutic implications. Tyrosine kinase inhibitors (TKIs) that specifically target RET can be used to treat patients with this fusion gene. The G810R mutation may also be targeted for personalized medicine approaches, potentially improving patient outcomes.
A: The KIF5B-RET-G810R fusion gene is detected through various molecular diagnostic techniques, such as fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), and next-generation sequencing (NGS). These methods can identify the specific fusion event and the G810R mutation, allowing for accurate diagnosis and prognosis of patients with tumors harboring this fusion gene.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Human KIF5B-RET-G810R Stable Cell Line - BaF3 has a minimal environmental footprint, as it is produced and cultured in a controlled laboratory setting, reducing the need for animal testing and minimizing waste.
This cell line is well-received in the scientific community due to its potential to advance understanding and treatment of KIF5B-RET-G810R-driven cancers, aligning with societal values of medical progress and ethical research.
The Human KIF5B-RET-G810R Stable Cell Line - BaF3 demonstrates high efficacy in experimental settings, providing consistent and reliable results that contribute to the development of targeted therapies and personalized medicine approaches.
The cell line exhibits good immunogenic properties, making it a valuable tool for immunotherapy research and the development of vaccines or other immune-based treatments against KIF5B-RET-G810R-positive cancers.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
